Hepatorenal syndrome - Pipeline Insight, 2024

This “Hepatorenal syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatorenal syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatorenal syndrome Understanding

Hepatorenal syndrome: Overview

Skin and soft tissue infections (SSTIs) refer to a wide clinical spectrum of common infectious diseases that often require acute treatment and inpatient hospital admission. Complicated SSTIs (c SSTIs) are the most severe, involving deeper soft tissues and include infective cellulitis, ulcer or wound site infections, surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the commonest cause of c SSTIs. The management of cSSTIs normally involves a combination of surgical procedures and antibiotic therapy. The main choice of antibiotic depends on theclinicalpresentation.

Hepatorenal syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatorenal syndrome pipeline landscape is provided which includes the disease overview and Hepatorenal syndrome treatment guidelines. The assessment part of the report embraces, in depth Hepatorenal syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatorenal syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatorenal syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Hepatorenal syndrome.

Hepatorenal syndrome Emerging Drugs Chapters

This segment of the Hepatorenal syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatorenal syndrome Emerging Drugs

Ambrisentan: Noorik Bio Pharmaceuticals Ambrisentan, a small molecule, is a well-characterised endothelin receptor antagonist. Ambrisentan has the ability to block the effects of endothelin on both the ETA and ETB receptors. However, the blockade of each receptor occurs at different concentrations of Ambrisentan in blood: Ambrisentan blocks the ETA receptor at significantly lower concentrations than those required to block the ETB receptor. The drug is in phase 2 of clinical trials for the treatment of Hepatorenalsyndrome.

Ifetroban: Cumberland Pharmaceuticals Ifetroban is a potent antagonist of the thromboxane prostanoid (TPr) receptor, which has various functions including smooth muscle contraction, platelet aggregation and inflammation. Preclinical work on this molecule demonstrated that blocking TPr with ifetroban improves cardiac survival while increasing cardiac output in multiple animal models. The drug is in phase 2 of clinical trials for the treatment of Hepatorenal syndrome.

Hepatorenal syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Hepatorenal syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hepatorenal syndrome

There are approx. 3+ key companies which are developing the therapies for Hepatorenal syndrome. The companies which have their Hepatorenal syndrome drug candidates in the mid to advanced stage, i.e. phase II include, Noorik Biopharmaceuticals and others.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hepatorenal syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatorenal syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatorenal syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatorenal syndrome drugs.

Hepatorenal syndrome Report Insights

• Hepatorenal syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatorenal syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatorenal syndrome drugs?
• How many Hepatorenal syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatorenal syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatorenal syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatorenal syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Noorik Biopharmaceuticals
• Cumberland Pharmaceuticals
• BioVie

Key Products

• Ambrisentan
• Ifetroban
• Terlipressin